{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:05:40Z","timestamp":1790179540756,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"DOI":"10.1007\/s12031-026-02560-7","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:33:29Z","timestamp":1781577209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarker Based ARIA Stress Test: A Proposed Conceptual Framework for Dynamic Biomarker-Guided ARIA Risk Stratification in Anti-Amyloid Immunotherapy for Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"76","author":[{"given":"Shihshuan","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7895-2617","authenticated-orcid":false,"given":"Shenghan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"4","key":"2560_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/WCO.0000000000001388","volume":"38","author":"F Agosta","year":"2025","unstructured":"Agosta F, Cecchetti G, Spinelli EG et al (2025) MRI protocols and sequences for amyloid-related imaging abnormalities monitoring in Alzheimer\u2019s disease patients treated with monoclonal antibodies. Curr Opin Neurol 38(4):289\u2013297. https:\/\/doi.org\/10.1097\/WCO.0000000000001388","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"2560_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J et al (2022) Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis 9(2):211\u2013220. https:\/\/doi.org\/10.14283\/jpad.2022.21","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"2560_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/aas.14033","volume":"66","author":"M Barbu","year":"2022","unstructured":"Barbu M, Jonsson K, Zetterberg H et al (2022) Serum biomarkers of brain injury after uncomplicated cardiac surgery: secondary analysis from a randomized trial. Acta Anaesthesiol Scand 66(4):447\u2013453. https:\/\/doi.org\/10.1111\/aas.14033","journal-title":"Acta Anaesthesiol Scand"},{"issue":"20","key":"2560_CR28","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ et al (2023) Two Phase 3 Trials of Gantenerumab in Early Alzheimer\u2019s Disease. N Engl J Med 389(20):1862\u20131876","journal-title":"N Engl J Med"},{"issue":"3","key":"2560_CR10","doi-asserted-by":"publisher","first-page":"e00535","DOI":"10.1016\/j.neurot.2025.e00535","volume":"22","author":"O Bonnar","year":"2025","unstructured":"Bonnar O, Eyre B, van Veluw SJ (2025) Perivascular brain clearance as a therapeutic target in cerebral amyloid angiopathy and Alzheimer\u2019s disease. Neurotherapeutics 22(3):e00535. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00535","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2560_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"2560_CR11","doi-asserted-by":"publisher","first-page":"e71038","DOI":"10.1002\/alz.71038","volume":"21","author":"Q Chen","year":"2025","unstructured":"Chen Q, Wen Q, Zhong T, Liu J, Gao H (2025) Deep cervical lymphaticovenous anastomosis for Alzheimer\u2019s disease: a narrative review. Alzheimers Dement 21(12):e71038. https:\/\/doi.org\/10.1002\/alz.71038","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2560_CR21","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1212\/WNL.0000000000207358","volume":"101","author":"C Cicognola","year":"2023","unstructured":"Cicognola C, Mattsson-Carlgren N, van Westen D et al (2023) Associations of CSF PDGFR\u03b2 with aging, blood-brain barrier damage, neuroinflammation, and Alzheimer disease pathologic changes. Neurology 101(1):e30\u2013e39. https:\/\/doi.org\/10.1212\/WNL.0000000000207358","journal-title":"Neurology"},{"issue":"1","key":"2560_CR22","doi-asserted-by":"publisher","first-page":"e70079","DOI":"10.1002\/dad2.70079","volume":"17","author":"G Di Molfetta","year":"2025","unstructured":"Di Molfetta G et al (2025) Inflammation biomarkers and Alzheimer\u2019s disease: A pilot study using NULISAseq. Alzheimers Dement (Amst) 17(1):e70079","journal-title":"Alzheimers Dement (Amst)"},{"key":"2560_CR7","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP (2024) Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci 18:1326784. https:\/\/doi.org\/10.3389\/fnins.2024.1326784","journal-title":"Front Neurosci"},{"issue":"3","key":"2560_CR25","doi-asserted-by":"publisher","first-page":"e70116","DOI":"10.1002\/alz.70116","volume":"21","author":"R Durcan","year":"2025","unstructured":"Durcan R et al (2025) Novel blood-based proteomic signatures across multiple neurodegenerative diseases. Alzheimers Dement 21(3):e70116","journal-title":"Alzheimers Dement"},{"issue":"9","key":"2560_CR15","doi-asserted-by":"publisher","first-page":"e214220","DOI":"10.1212\/WNL.0000000000214220","volume":"105","author":"NC Edwards","year":"2025","unstructured":"Edwards NC, Lao P, Alshikho MJ et al (2025) Alzheimer disease, vascular disease, and blood-brain barrier permeability biomarkers in middle-aged adults. Neurology 105(9):e214220. https:\/\/doi.org\/10.1212\/WNL.0000000000214220","journal-title":"Neurology"},{"issue":"1","key":"2560_CR26","doi-asserted-by":"publisher","first-page":"46409","DOI":"10.1038\/s41598-026-46409-w","volume":"16","author":"MF Farinas","year":"2026","unstructured":"Farinas MF et al (2026) Evaluation of serum as an alternative matrix to plasma for NULISA-based proteomic blood biomarker measurements. Sci Rep 16(1):46409","journal-title":"Sci Rep"},{"issue":"1","key":"2560_CR29","doi-asserted-by":"publisher","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm HP et al (2023) Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs 15(1):2261509","journal-title":"MAbs"},{"issue":"10","key":"2560_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00415-025-13456-8","volume":"272","author":"X Guo","year":"2025","unstructured":"Guo X, Yue R, Cui Z et al (2025) Advances of therapeutic strategies for Alzheimer\u2019s disease. J Neurol 272(10):705. https:\/\/doi.org\/10.1007\/s00415-025-13456-8","journal-title":"J Neurol"},{"issue":"8","key":"2560_CR34","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2560_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3348\/jksr.2024.0140","volume":"86","author":"SY Jeong","year":"2025","unstructured":"Jeong SY, Suh CH, Lim JS et al (2025) Anti-amyloid imaging abnormality in the era of anti-amyloid beta monoclonal antibodies: recent updates for the radiologist. J Korean Soc Radiol 86(1):17\u201332. https:\/\/doi.org\/10.3348\/jksr.2024.0140","journal-title":"J Korean Soc Radiol"},{"issue":"5","key":"2560_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.26511","volume":"92","author":"N Joseph-Mathurin","year":"2022","unstructured":"Joseph-Mathurin N et al (2022) Amyloid-related imaging abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: lessons from a trial in dominantly inherited Alzheimer disease. Ann Neurol 92(5):729\u2013744","journal-title":"Ann Neurol"},{"issue":"1","key":"2560_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13024-024-00753-5","volume":"19","author":"LM Li","year":"2024","unstructured":"Li LM et al (2024) High-dimensional proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease. Mol Neurodegener 19(1):68","journal-title":"Mol Neurodegener"},{"issue":"3","key":"2560_CR1","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.tjpad.2026.100477","volume":"13","author":"SY Moon","year":"2026","unstructured":"Moon SY, Chen TF, Lee BC et al (2026) A regional framework for the detection and management of ARIA with anti-amyloid therapies in early Alzheimer\u2019s disease in Asia. J Prev Alzheimers Dis 13(3):100477. https:\/\/doi.org\/10.1016\/j.tjpad.2026.100477","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"2560_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13195-025-01912-6","volume":"17","author":"M Noguchi-Shinohara","year":"2025","unstructured":"Noguchi-Shinohara M, Yoshinobu T, Ozaki T et al (2025) Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data. Alzheimers Res Ther 17(1):251. https:\/\/doi.org\/10.1186\/s13195-025-01912-6","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2560_CR33","first-page":"100006","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD et al (2025) Donanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis 12(1):100006","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"2560_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Sperling RA, Donohue MC et al (2023) The AHEAD 3\u201345 Study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement 19(4):1227\u20131233. https:\/\/doi.org\/10.1002\/alz.12748","journal-title":"Alzheimers Dement"},{"issue":"S6","key":"2560_CR27","doi-asserted-by":"publisher","first-page":"e103048","DOI":"10.1002\/alz70860_103048","volume":"21","author":"MN Sabbagh","year":"2025","unstructured":"Sabbagh MN et al (2025) Indirect Treatment Comparison of ARIA Outcomes for Lecanemab and Donanemab. Alzheimers Dement 21(S6):e103048","journal-title":"Alzheimers Dement"},{"issue":"12","key":"2560_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40266-025-01253-x","volume":"42","author":"CP Schreiber","year":"2025","unstructured":"Schreiber CP, Kovacik A, Bishop J, Helman J (2025) Amyloid-related imaging abnormalities (ARIA) in the context of Alzheimer\u2019s disease and amyloid-targeting therapies: an introduction for advanced practice providers. Drugs Aging 42(12):1103\u20131111. https:\/\/doi.org\/10.1007\/s40266-025-01253-x","journal-title":"Drugs Aging"},{"issue":"8","key":"2560_CR30","doi-asserted-by":"publisher","first-page":"100214","DOI":"10.1016\/j.tjpad.2025.100214","volume":"12","author":"D Sehlin","year":"2025","unstructured":"Sehlin D et al (2025) Bispecific brain-penetrant antibodies for treatment of Alzheimer\u2019s disease. J Prev Alzheimers Dis 12(8):100214","journal-title":"J Prev Alzheimers Dis"},{"key":"2560_CR6","doi-asserted-by":"publisher","first-page":"102981","DOI":"10.1016\/j.arr.2025.102981","volume":"114","author":"GH Shim","year":"2025","unstructured":"Shim GH, Lau ECY, Huynh ALH, Lu CY, Tan ECK (2025) Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease: a systematic review and meta-analysis. Ageing Res Rev 114:102981. https:\/\/doi.org\/10.1016\/j.arr.2025.102981","journal-title":"Ageing Res Rev"},{"issue":"6","key":"2560_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"issue":"6","key":"2560_CR20","doi-asserted-by":"publisher","first-page":"103661","DOI":"10.5498\/wjp.v15.i6.103661","volume":"15","author":"L Sun","year":"2025","unstructured":"Sun L, Xu MR, Zhou CY et al (2025) Diagnostic dynamic contrast-enhanced magnetic resonance imaging blood-brain barrier assessment combined with plasma biomarkers for mild cognitive impairment. World J Psychiatry 15(6):103661. https:\/\/doi.org\/10.5498\/wjp.v15.i6.103661","journal-title":"World J Psychiatry"},{"issue":"1","key":"2560_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","volume":"18","author":"X Taylor","year":"2023","unstructured":"Taylor X, Clark IM, Fitzgerald GJ et al (2023) Amyloid-beta (A\u03b2) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer\u2019s disease mice. Mol Neurodegener 18(1):59. https:\/\/doi.org\/10.1186\/s13024-023-00649-w","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2560_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, Noristani HN, Fitzgerald GJ et al (2024) Amyloid-beta (A\u03b2) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener 19(1):77. https:\/\/doi.org\/10.1186\/s13024-024-00758-0","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2560_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"issue":"1","key":"2560_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12987-025-00737-7","volume":"22","author":"MR Vega","year":"2025","unstructured":"Vega MR et al (2025) Transferrin receptor-binding blood-brain barrier shuttle enhances brain delivery and plaque-clearing efficacy of a therapeutic anti-A\u03b2 antibody. Fluids Barriers CNS 22(1):37","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"2560_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1177\/13872877251404505","volume":"109","author":"A Villarejo Galende","year":"2025","unstructured":"Villarejo Galende A, Gonzalez-Sanchez M, Hilario A et al (2025) Severe symptomatic amyloid-related imaging abnormalities in Alzheimer\u2019s disease: two case reports and systematic review of reported cases. J Alzheimers Dis 109(3):1099\u20131116. https:\/\/doi.org\/10.1177\/13872877251404505","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"2560_CR19","doi-asserted-by":"publisher","first-page":"e70611","DOI":"10.1002\/alz.70611","volume":"21","author":"AE Walter","year":"2025","unstructured":"Walter AE, Pike JR, Coresh J et al (2025) Traumatic brain injury, changes in plasma amyloid, tau, and neurodegenerative biomarkers, and dementia risk. Alzheimers Dement 21(9):e70611. https:\/\/doi.org\/10.1002\/alz.70611","journal-title":"Alzheimers Dement"},{"key":"2560_CR14","doi-asserted-by":"publisher","first-page":"1107436","DOI":"10.3389\/fnins.2023.1107436","volume":"17","author":"P Wijewisinghe","year":"2023","unstructured":"Wijewisinghe P, Bhopale E, Bhatt P, Bhatt P, Cao Y, Sukumar P (2023) Ergothioneine improves A\u03b2 clearance via blood-derived phagocytic cells and perivascular drainage in 5XFAD mice. Front Neurosci 17:1107436. https:\/\/doi.org\/10.3389\/fnins.2023.1107436","journal-title":"Front Neurosci"},{"issue":"1","key":"2560_CR23","doi-asserted-by":"publisher","first-page":"e14535","DOI":"10.1002\/alz.14535","volume":"21","author":"X Zeng","year":"2025","unstructured":"Zeng X et al (2025) Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort. Alzheimers Dement 21(1):e14535","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-026-02560-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12031-026-02560-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-026-02560-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:34:11Z","timestamp":1790177651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12031-026-02560-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2560"],"URL":"https:\/\/doi.org\/10.1007\/s12031-026-02560-7","relation":{},"ISSN":["1559-1166"],"issn-type":[{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This manuscript presents a conceptual framework and proposed trial protocol. No human participants, human data, human tissue, or animals were involved in this study.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"106"}}